Pipeline dossier

NIH & clinical-trial pipeline signals for NOVO NORDISK A S (NVO)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for NVO, mapped to public ticker NVO (CIK 0000353278). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingNVO55% conf

NOVO NORDISK A S (NVO) — trial primary completion in ~10 days

Upstream (observed)
Clinical trial status (n/a) — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

JSON API for this entity →